Author

M. M. Pillai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1

Frequent Co-Authors

A. K. Gupta· 3 shared K. M. Neugebauer· 2 shared N. Neuenkirchen· 2 shared A. K. Verma· 1 shared A. Olazabal Herrero· 1 shared A. Pellagatti· 1 shared A. Shastri· 1 shared A. Verma· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. K. Gupta

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Transcription elongation defects link oncogenic splicing factor mutations to targetable alterations in chromatin landscape

P. C. Boddu, A. K. Gupta, R. Roy, B. De La Pena Avalos, A. Olazabal Herrero, N. Neuenkirchen, J. T. Zimmer, N. S. Chandhok, D. King, Y. Nannya, S. Ogawa, H. Lin, M. D. Simon, E. Dray, G. Kupfer, , M. M. Pillai

This paper shows that mutations in SF3B1 and U2AF1 cause transcription elongation defects leading to chromatin changes and identifies targeting the Sin3/HDAC complex as a potential therapy.

bioRxiv · Feb 25, 2023Cancer Biology

Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry

N. Bai, Y. Adeshina, I. Bychkov, Y. Xia, R. Gowthaman, S. A. Miller, A. K. Gupta, D. K. Johnson, L. Lan, E. A. Golemis, P. B. Makhov, L. Xu, M. M. Pillai, Y. Boumber, J. Karanicolas

This paper designs inhibitors for Musashi proteins MSI1 and MSI2 by mimicking hotspot pharmacophores from protein-RNA complexes, showing specificity and activity in multiple assays.

bioRxiv · Jan 9, 2023 · PreprintBiochemistry

Activation of targetable inflammatory immune signaling is seen in Myelodysplastic Syndromes with SF3B1 mutations

G. Choudhary, A. Pellagatti, B. Agianian, M. Smith, T. D. Bhagat, S. Gordon-Mitchell, S. Pandey, N. Shah, S. Aluri, L. Schwartz, V. Steeples, R. Booher, M. Ramachandra, M. Samson, M. Carbajal, , A. Verma

This study identifies a longer, oncogenic IRAK4 isoform caused by SF3B1 mutations in MDS/AML, which is targetable by IRAK4 inhibition.

bioRxiv · Mar 9, 2022Cancer Biology

Integrative genome-wide analysis reveals EIF3A as a key downstream regulator of translational repressor protein Musashi 2 (MSI2)

S. Karmakar, O. Ramirez, K. V. Paul, A. K. Gupta, V. Botti, I. R. d. l. Mozos, N. Neuenkirchen, R. J. Ross, K. M. Neugebauer, M. M. Pillai

The paper identifies EIF3A as a direct target of MSI2 and shows that MSI2 represses EIF3A translation, which amplifies its effects on the proteome.

bioRxiv · Feb 6, 2021Cancer Biology